Vibozilimod

  Cat. No.:  DC47017   Featured
Chemical Structure
1403232-33-6
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Vibozilimod (example 33) is a S1p1 receptor agonist (extracted from patent WO2012140020A1).
Cas No.: 1403232-33-6
Chemical Name: Vibozilimod
Synonyms: Vibozilimod;0GYJ8CJ1DE;Vibozilimod [INN];1-((4-(5-(3-Chloro-4-(2-methylpropyl)phenyl)-1,2,4-oxadiazol-3-yl)phenyl)methyl)-4-((2-methoxyethoxy)methyl)-4-piperidinecarboxylic acid;4-Piperidinecarboxylic acid, 1-((4-(5-(3-chloro-4-(2-methylpropyl)phenyl)-1,2,4-oxadiazol-3-yl)phenyl)methyl)-4-((2-methoxyethoxy)methyl)-
SMILES: ClC1C([H])=C(C([H])=C([H])C=1C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])C1=NC(C2C([H])=C([H])C(=C([H])C=2[H])C([H])([H])N2C([H])([H])C([H])([H])C(C(=O)O[H])(C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])[H])C([H])([H])C2([H])[H])=NO1
Formula: C29H36ClN3O5
M.Wt: 542.0662
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication: [1]. Marc Capet, et al. Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists. Patent. WO2012140020A1.
Description: Vibozilimod (example 33) is a S1p1 receptor agonist (extracted from patent WO2012140020A1).
References: [1]. Marc Capet, et al. Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists. Patent. WO2012140020A1.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC73453 ACT-1016-0707 ACT-1016-0707 is a potent, selective, and orally active lysophosphatidic acid receptor subtype 1 receptor (LPA1 receptor, LPAR1) antagonist with IC50 of 3.1 nM, highly selective over LPAR2 or LPAR3.
DC70752 S1P5-IN-15 S1P5-IN-15 is a potent, selective, orally active and brain-penetrant S1P5 antagonist with IC50 of 0.1 nM, no effect on S1P1-4.
DC47017 Vibozilimod Vibozilimod (example 33) is a S1p1 receptor agonist (extracted from patent WO2012140020A1).
DC28233 CYM 50308 CYM50308 is a potent, selective and high affinity sphingosine-1-phosphate receptor 4 (S1P4-R) agonist with an EC50 of 56 nM. CYM50308 displays 37-fold more selective for S1P4-R than S1P5-R. CYM50308 has no activity at S1P1-R, S1P2-R and S1P3-R subtypes at concentrations up to 25 μM.
DC10561 GSK-2018682 GSK-2018682 is a sphingosine 1 phosphate receptor (S1PR)-1 agonist potentially for the treatment of multiple sclerosis.
DC10923 TAK-615 TAK-615 (TAK615) is a potent, selective, negative allosteric modulator (NAM) of the LPA1 receptor, partially inhibits the LPA response with IC50 of 91 nM (60% at 10 uM) in calcium mobilisation assays..
DC10924 BMS986202 BMS-986202 is a clinical Tyk2 inhibitor that binds to Tyk2 JH2 with IC50 of 0.19 nM and shows remarkably selectivity over other kinases including Jak family members.
DC8622 AM095 free acid AM095 is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.
DC11754 AD 2900 AD 2900 (AD2900, AD-2900) is a novel potent, broad S1P receptor antagonist with IC50 of 3.8, 3.2, 6.2, 5.9 and 0.405 uM for S1P1, 2, 3, 4 and 5 respectively.
X